IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide.

Neurology
H J DubbinkM J van den Bent

Abstract

Mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) have been implicated in tumorigenesis of gliomas. Patients with high-grade astrocytomas with IDH1 or IDH2 mutations were reported to have a better survival, but it is unknown if this improved survival also holds for low-grade astrocytoma and whether these mutations predict outcome to specific treatment. We retrospectively investigated the correlation of IDH1 and IDH2 mutations with overall survival and response to temozolomide in a cohort of patients with dedifferentiated low-grade astrocytomas treated with temozolomide at the time of progression after radiotherapy. IDH1 mutations were present in 86% of the 49 progressive astrocytomas. No mutations in IDH2 were found. Presence of IDH1 mutations were early events and significantly improved overall survival (median survival 48 vs 98 months), but did not affect outcome of temozolomide treatment. These results indicate that IDH1 mutations identify a subgroup of gliomas with an improved survival, but are unrelated to the temozolomide response.

Citations

Aug 18, 2010·Acta Neuropathologica·Markus J RiemenschneiderGuido Reifenberger
Mar 21, 2013·Acta Neuropathologica·Craig Horbinski
Jul 8, 2011·Brain Tumor Pathology·Ichiyo ShibaharaTeiji Tominaga
Sep 8, 2012·Current Treatment Options in Oncology·Adriana Olar, Kenneth D Aldape
Mar 20, 2012·Current Neurology and Neuroscience Reports·Ghazaleh TabatabaiMichael Weller
Jan 5, 2002·Early Human Development·M Rivero-Urgëll, A Santamaría-Orleans
Nov 4, 2010·Nature Reviews. Neurology·T David Bourne, David Schiff
Aug 24, 2012·Current Opinion in Oncology·Aurélien ViaccozFrançois Ducray
Oct 18, 2011·Current Opinion in Neurology·Changcun GuoHai Yan
Jan 13, 2012·Science Translational Medicine·Philippe Metellus, Dominique Figarella-Branger
Oct 31, 2012·Neurology·Brett J TheelerJohn F De Groot
Mar 13, 2014·PloS One·Xiaowei GuanJill S Barnholtz-Sloan
Aug 23, 2011·Journal of Neurosurgery·David Schiff
Nov 3, 2011·Journal of Neurosurgery·Nader SanaiMitchel S Berger
Jan 22, 2013·Journal of Neurosurgery·Catherine GozéHugues Duffau
Apr 16, 2013·Journal of Neurosurgery·Tiffany R HodgesJohn H Sampson
Sep 15, 2014·Neuroscience Letters·Elena BogdanovicMarc G Jeschke
Sep 24, 2010·Acta Neuropathologica·Ghazaleh TabatabaiMichael Weller
Dec 2, 2014·Neurosurgical Focus·Sameer AgnihotriGelareh Zadeh
Nov 20, 2012·Current Opinion in Neurology·Markus Weiler, Wolfgang Wick
Oct 1, 2011·Expert Review of Neurotherapeutics·Brian M Alexander, Minesh P Mehta
May 11, 2011·Expert Review of Anticancer Therapy·François DucrayMarc Sanson
Jan 3, 2013·British Journal of Neurosurgery·R MaR Stacey
Jan 12, 2016·Current Neurology and Neuroscience Reports·Emilie Le RhunMarc C Chamberlain
Dec 15, 2012·Cancer Genetics·McKinsey L Goodenberger, Robert B Jenkins
Mar 6, 2013·Surgical Pathology Clinics·Craig Horbinski
Jul 4, 2012·Neurosurgery Clinics of North America·Won Kim, Linda M Liau
May 10, 2015·Pharmacology & Therapeutics·Seth J Parker, Christian M Metallo
Mar 27, 2012·Annals of Diagnostic Pathology·Aditya RaghunathanGregory N Fuller
Sep 3, 2011·Revue neurologique·M RossettoM Sanson
Sep 13, 2011·Revue neurologique·F Ducray
Aug 10, 2010·Trends in Molecular Medicine·Lenny DangShinsan M Su
Sep 24, 2010·Seminars in Diagnostic Pathology·Craig Horbinski
Mar 5, 2016·Journal of Hematology & Oncology·Francesco Gatto, Jens Nielsen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Astrocytes

Astrocytes are glial cells that support the blood-brain barrier, facilitate neurotransmission, provide nutrients to neurons, and help repair damaged nervous tissues. Here is the latest research.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Marc SansonJean-Yves Delattre
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Sumihito NobusawaHiroko Ohgaki
© 2022 Meta ULC. All rights reserved